Valuation

PURRHyperliquid Strategies Inc

StockNasdaqUnited StatesHealth careEU retail investors: available

+1.1% today

No score: too little data.

No dividend.

Hyperliquid Strategies Inc (PURR) valuation against sector peers: P/E 9.6 (sector median 30.9), P/B 0.7, EV/EBIT 1.7.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricPURRSector medianvs median
P/E9.630.9 · n=15969% below
P/B0.74.0 · n=30782% below
P/S—4.1 · n=299—
EV/EBIT1.725.6 · n=14693% below
Free-cash-flow yield—1.4% · n=288—
Dividend yield0.00%0.00% · n=362—
Return on equity27.6%−2.1% · n=308—
Return on invested capital30.4%0.6% · n=2824,624% above
Gross margin—63.3% · n=205—
Net debt / EBITDA—1.27 · n=151—

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co48.233.0—1.5%0.6%6/10
JNJJohnson & Johnson42.28.3—3.0%1.9%8/10
ABBVAbbVie50.3—27.73.6%2.9%6/10
MRKMerck149.58.2—4.0%2.3%8/10
UNHUnitedHealth22.43.417.16.4%2.3%10/10
TMOThermo Fisher Scientific37.84.935.72.8%0.3%9/10
AMGNAmgen26.817.523.23.8%2.1%8/10
GILDGilead Sciences—16.1—6.6%1.9%5/10
ABTAbbott40.73.832.93.5%2.8%6/10
PFEPfizer41.31.9—7.1%7.4%1/10

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 05 Nov 2026